The Carlyle Group completes NBTY acquisition
NEW YORK Global alternative asset manager The Carlyle Group and NBTY on Monday announced that Carlyle has completed its $4 billion acquisition of NBTY.
Pursuant to the terms of the merger agreement, NBTY’s stockholders are entitled to receive $55 in cash, without interest, less any applicable withholding taxes, for each share of NBTY common stock owned by them.
As a result of the merger, NBTY’s common stock no longer will be listed for trading on the New York Stock Exchange.
FDA tentatively approves generic Crestor
MUMBAI, India The Food and Drug Administration has given tentative approval to a generic cholesterol drug made by Sun Pharmaceutical Industries.
Sun announced Wednesday the tentative approval of rosuvastatin calcium tablets in the 5-mg, 10-mg, 20-mg and 40-mg strengths.
The drug is a generic version of AstraZeneca’s Crestor, which had annual sales of around $3.4 billion in the United States, according to Sun. Sun did not disclose when it would begin marketing its version of the drug, though Crestor will lose patent protection for use in adults in December 2021, according to FDA data.
Walgreens names SVP pharmaceutical development, market access
DEERFIELD, Ill. Walgreens announced Thursday that Jeffrey Berkowitz, a former SVP at drug maker Merck, has joined the company.
Berkowitz will serve as Walgreens’ SVP pharmaceutical development and market access, responsible for the overall pharmacy contracting strategy for the company, both on the pharmaceutical manufacturing side and on the retail payer side, the drug store chain said. He will report to Walgreens’ pharmacy services president Kermit Crawford.
“As we continue our efforts to transform community pharmacy, Jeff will play a vital role in working with our partners in the pharmaceutical industry, and across the entire healthcare sector, to develop strategies in collaboration with our sales and services organization that will provide better adherence and clinical outcomes for patients,” Crawford said. “In addition, Jeff’s exceptional experience, expertise and track record of growth and success in the pharmaceutical industry will be important to further enhancing our pharmacy, health-and-wellness solutions.”
Prior to joining Walgreens, Berkowitz served as SVP global market access at Merck, part of the Merck global human health leadership team, responsible for all activity related to access, pricing, payer marketing, health outcomes and health technology assessments worldwide.